论文部分内容阅读
恶性病患者常伴有止血障碍、高凝或低凝。由于凝血因子的消耗,高凝之后可以继发低凝。例如肿瘤细胞周围可见到纤维蛋白沉积,O’Meara认为这是由于肿瘤本身的促凝活力所致,并从而为肿瘤生长提供了条件。此外,在体外实验中可看到许多人类肿瘤细胞克隆能促进血小板聚集。血小板聚集伴有血小板特异性蛋白——β-血小板球蛋白(β-TG)的释放,因此β-TG的血浆水平可反映体内血小板的聚集。作者对恶性疾病患者作了血浆β-TG的观察。
Malignant patients often accompanied by hemostasis, hypercoagulability or low coagulation. Due to the consumption of coagulation factors, hypercoagulation can be secondary to low coagulation. For example, deposition of fibrin is seen around tumor cells, which O’Meara believes is due to the procoagulant activity of the tumor itself and thereby provides the conditions for tumor growth. In addition, it can be seen in vitro that many human tumor cell clones promote platelet aggregation. Platelet aggregation is accompanied by the release of platelet-specific protein, beta-thromboglobulin (β-TG), so the plasma level of beta-TG reflects platelet aggregation in vivo. The author of patients with malignant disease was observed plasma β-TG.